Skip to content

Clinical Study Evaluating the Effect of Virtual Reality on Reducing Patients' Anxiety During Wisdom Teeth Extraction

Clinical Study Evaluating the Effect of Virtual Reality on Reducing Anxiety in Patients Undergoing Wisdom Teeth Extraction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07273968
Acronym
SEREIN
Enrollment
60
Registered
2025-12-10
Start date
2026-04-10
Completion date
2027-09-01
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Anxiety, Oral Surgery, Third Molar Extraction

Brief summary

Dental anxiety is common during third molar extractions and may exacerbate pain perception. Local anesthesia does not prevent exposure to stress-inducing stimuli. Virtual reality (VR) combined with hypnotic scripts (HypnoVR®) provides immersive multisensory distraction. This study tests whether VR reduces perioperative anxiety and postoperative pain compared to local anesthesia alone.

Interventions

DEVICEVirtual reality HypnoVR® (VR headset + hypnotic software)

CE-marked class I device combining VR immersion with hypnotic text and music therapy to reduce anxiety and pain during oral surgery.

OTHERControl Group (No VR)

local anesthesia alone (no VR)

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-65 * Indication for extraction of 4 wisdom teeth or ≥2 mandibular wisdom teeth * ASA I-II * Written informed consent.

Exclusion criteria

* Visual/hearing impairment * Psychiatric disorders or psychotropics (\<8 weeks) * Claustrophobia * Heavy smoking \>10 cig/day * Previous radiotherapy (jaw) * ASA III-IV * Pregnancy * Antithrombotic therapy * Chemotherapy * Bisphosphonates * Uncontrolled diabetes * Severe anxiety requiring GA or pharmacological sedation * No health insurance affiliation.

Design outcomes

Primary

MeasureTime frameDescription
Anxiety reduction (MDAS questionnaire)Day 15-item validated scale, score range 5-25

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026